Research Communications of the 27(th) ECVIM-CA Congress: Intercontinental, Saint Julian's, Malta, 14th to 16th September 2017

Disclosures: No disclosures to report. Records of all cases diagnosed between 2004 and 2016 with eosinophilic bronchitis (EB) or idiopathic eosinophilic bronchopneumopathy (EBP) at four university hospitals in the UK were reviewed. Cases were excluded if full records were not available or if other pulmonary disease such as neoplasia or parasitic pneumonitis was identified. The following information was retrieved: breed, age, sex, weight, clinical signs, presence of eosinophilia, thoracic imaging findings, bronchoscopy results (classified as mild; moderate; severe), BALF cytology results (eosinophilic pleocytosis classified as mild 10-25%; moderate 25-50%; severe >50%), infectious disease screening and concurrent disease processes. The following subgroups were created: acute (<1 month of clinical signs) versus chronic (>1 month of clinical signs); EB1 (no radiographic changes or bronchial/peribronchial pattern) vs. EBP1 (interstitial / alveolar patterns) and EB2 (no radiographic changes) vs. EBP2 (any pulmonary pattern). Group comparisons by chi-square or Fisher's exact test were carried out in regards to age, weight, bronchoscopy score, presence of eosinophilia or bronchiectasis and degree of eosinophilia in BALF.